Blood clots can be very dangerous, especially for older people. A clot that forms in the leg is called deep vein thrombosis, and if it travels to the lungs, it becomes a pulmonary embolism.
These conditions together are known as venous thromboembolism, and they can lead to serious illness or even death.
Older adults are more likely to develop these clots, and they are also more likely to have complications during recovery. After a first clot, the risk of another one remains high, so many patients need to take blood-thinning medicine for a long time.
Doctors have several options when choosing a blood thinner, but it has not always been clear which one is best for older adults, especially those who are frail. Frailty means the body is weaker and less able to handle stress or illness. It can affect how drugs work and how likely side effects are.
A recent study published in the American Journal of Hematology aimed to answer this question. Researchers from the Hinda and Arthur Marcus Institute for Aging Research studied more than 18,000 older adults in the United States who had experienced blood clots.
They used Medicare data collected between 2015 and 2019. The study compared three common blood thinners: apixaban, rivaroxaban, and warfarin. Warfarin is an older drug that has been widely used for decades, while the other two are newer and are often seen as easier to use.
One of the main things the researchers measured was something called “home time.” This refers to how many days patients were able to stay at home instead of being in hospitals or care facilities. It is an important measure because it reflects a patient’s independence and quality of life.
The results showed that patients taking apixaban did better overall. They had fewer serious problems, including fewer repeat clots and a lower chance of dying within one year. They also had fewer major bleeding events, which is a key concern when using blood thinners.
In addition, patients on apixaban spent more days at home compared to those taking warfarin. This means they were less likely to need hospital care or extended stays in nursing facilities.
Rivaroxaban, on the other hand, did not show clear benefits over warfarin in preventing complications. It was also linked to fewer days at home compared to apixaban, suggesting it may not provide the same level of overall benefit.
The study also carefully looked at differences between frail and non-frail patients. While both groups benefited from apixaban, the advantage was more noticeable in patients who were not frail. This highlights the importance of considering each patient’s condition when choosing treatment.
Dr. Chanmi Park, the lead author, noted that treatment decisions for older adults are often complex. Doctors must consider not only the medical results but also what matters most to patients, such as staying independent and avoiding hospital stays.
Although this study provides strong evidence, it is important to understand its limits. Because it is based on existing data rather than a controlled experiment, it cannot fully prove that one drug directly causes better outcomes. Other factors, such as overall health or access to care, may also play a role.
Even so, the large size of the study and its focus on real-world patients make the findings very useful. It offers practical information that doctors can use when choosing a blood thinner for older patients.
In conclusion, this research suggests that apixaban may be a better option for many older adults recovering from blood clots. It appears to lower the risk of serious complications and allows patients to spend more time at home.
However, the best choice will depend on each individual’s health and needs, so decisions should always be made together with a healthcare provider.
If you care about wellness, please read studies about how ultra-processed foods and red meat influence your longevity, and why seafood may boost healthy aging.
For more health information, please see recent studies that olive oil may help you live longer, and vitamin D could help lower the risk of autoimmune diseases.
Source: Hebrew SeniorLife. Credit: Unsplash+
